Aeterna Zentaris (AEZS) Reports Encouraging Data from Perifosine Phase 1
Aeterna Zentaris Inc. (Nasdaq: AEZS) announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues. Data were presented yesterday by Brian H. Kushner, MD, of the Memorial Sloan-Kettering Cancer Center in New York, during a poster session at the Advances in Neuroblastoma Research Conference which is being held in Toronto, Canada.
You May Also Be Interested In
- Lilly (LLY) Reports Edivoxetine Missed Primary Endpoints in Phase III
- NuVasive (NUVA) Adds Life Tech (LIFE) CEO Lucier as Director
- China Auto Logistics (CALI) to Acquire Tianjin Zhonghe Auto Sales in ~$131M Deal
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!